Boehringer To Reduce Price Of Antiretroviral Nevirapine In Low-, Middle-Income Countries, Official Says
Main Category: HIV / AIDSAlso Included In: Pharma Industry / Biotech Industry
Article Date: 18 May 2007 - 1:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
German pharmaceutical company Boehringer Ingelheim will reduce the price of its antiretroviral drug nevirapine, sold under the brand name Viramune, by 50% and 90% in low- and middle-income countries, respectively, Alessandro Banchi, chair of the company's managing board, said recently in an interview, the Financial Times reports (Jack, Financial Times, 5/15). Nevirapine -- a low-cost medication that is used as a standard method of reducing mother-to-child HIV transmission in the developing world -- reduces the risk of MTC HIV transmission in repeat pregnancies. The drug is given in pill form to HIV-positive women during labor to avoid MTC transmission and in syrup form to infants within 72 hours of birth (Kaiser Daily HIV/AIDS Report, 2/10/06).
According to the Times, the drug will cost 60 cents per patient daily in 78 low-income countries and $1.20 per patient daily in 67 middle-income countries. In developed countries, the drug costs between $10 and $14 per patient daily. The company also will waive a 5% royalty fee, reporting requirements and other existing obligations for generic drug producers that have World Health Organization approval to make nevirapine using voluntary licenses.
"We want to solve the problem (of access) once and for all," Banchi said, adding, "Preferential pricing is the only way how we can meet both conflicting needs in the fight against AIDS." The company "can refinance [its] high research and development costs for innovative, new treatments by the established price system in industrialized countries and can offer affordable medicines to patients in poor countries who otherwise cannot afford antiretroviral medication," Banchi said (Financial Times, 5/15).
"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our hiv / aids section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/71184.php>
APA
http://www.medicalnewstoday.com/releases/71184.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



